Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 03, 2015 5:46 PM ET

Company Overview of Sanaria, Inc.

Company Overview

,  

United States

Key Executives for Sanaria, Inc.

Sanaria, Inc. does not have any Key Executives recorded.

Sanaria, Inc. Key Developments

Cryoport and Sanaria Expand Logistics Partnership Supporting Malaria Vaccines

Cryoport, Inc. announced that the Company is enhancing its cryogenic logistics support of its Sanaria partnership, which includes Sanaria's production of malaria vaccine as well as its research and development efforts.

Sanaria's Malaria Vaccine Yields Unprecedented Protection in Phase 1 Clinical Trial

Results of a phase I clinical trial of the Sanaria(R) PfSPZ Vaccine to combat malaria, published in the online issue of Science magazine, show that the vaccine provided complete protection against malaria in subjects who were exposed to Plasmodium falciparum parasites. Plasmodium falciparum is the malaria parasite that causes more than 600,000 deaths annually. The current trial was primarily funded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) with additional support from the Naval Medical Research Center and Sanaria. Sanaria has also received research support and funding from multiple other institutions in the United States, Europe, and Africa during the past decade and will continue its fund-raising efforts to expand its research and clinical programs. In the clinical trial reported in Science, volunteers received intravenous injections of Sanaria(R) PfSPZ Vaccine, which consists of live, weakened, purified malaria parasites that do not cause illness. None of the six volunteers who received the higher dosage developed malaria after being bitten by malaria parasite-infected (disease transmitting) mosquitoes. The trial included 40 adult volunteers, ages 20-44, enrolled, vaccinated and assessed under the direction of the principal investigator, Robert Seder, M.D., and clinical team at the Vaccine Research Center, NIAID, NIH, Bethesda, MD.

Similar Private Companies By Industry

Company Name Region
Blue Ridge Country Club United States
Great Bend Supermarkets Inc. United States
Amerisource Heritage Corporation United States
Win-eldrich Gold, Inc. United States
Renascions, Inc United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sanaria, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.